Why Is SELLAS LIFE SCIENCES (SLS) Stock Down Today?

SLS stock is down 8.15% at $14.20 as of the latest trade, following a sharp intraday decline after opening near its 52-week high. The move reflects uncertainty around the status of Sellas Life Sciences’ Phase 3 REGAL trial for its AML candidate, which has been a key focus for investors. Despite recent retail speculation about the trial reaching a milestone, the company has not confirmed the 80th event, contributing to volatility.

What Happened

The stock opened at $15.49 and briefly touched a high of $15.75 early in the session before declining sharply. By midday, it had fallen to $13.91, a level that marked a 42% pullback from its June high of $15.88. The sell-off followed mixed signals from the market, including a German report claiming the trial hit a key milestone and a lack of confirmation from Sellas. Retail traders on platforms like r/wallstreetbets have expressed both optimism and skepticism, with some calling the stock oversold and others sharing anecdotal gains.

What The Data Shows

The stock has traded in a wide range over the past 52 weeks, from $1.39 to $15.88, and is currently near the upper end of its recent rebound. Over the last eight sessions, it rose 28.1% from $11.62 to $14.89. The session’s volume of 6.2 million shares is 0.7 times the 3-month average. Options activity has also been skewed, with $6.9 million in call premium traded compared to $0 in puts, and the largest single print reaching $4.1 million. The stock has printed 13 fresh 52-week lows on August 24.

What To Watch

Investors will be watching for confirmation of the 80th event in the Phase 3 REGAL trial, which could serve as a major catalyst. No earnings date is scheduled in the near term, but coverage breadth and options flows will be key indicators of market sentiment.